Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.

ABSTRACT:

Background

Liquid biopsies have demonstrated that the constitutively active androgen receptor splice variant-7 (AR-V7) associates with reduced response and overall survival from endocrine therapies in castration-resistant prostate cancer (CRPC). However, these studies provide little information pertaining to AR-V7 expression in prostate cancer (PC) tissue.

Methods

Following generation and validation of a potentially novel AR-V7 antibody for IHC, AR-V7 protein expression was determined for 358 primary prostate samples and 293 metastatic biopsies. Associations with disease progression, full-length androgen receptor (AR-FL) expression, response to therapy, and gene expression were determined.

Results

We demonstrated that AR-V7 protein is rarely expressed (<1%) in primary

SUBMITTER: Sharp A 

PROVIDER: S-EPMC6307949 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature